Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National Lymphocare Study

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3368-3375

  Friedberg, Jonathan W ^a   Byrtek, Michelle ^c   Link, Brian K ^d   Flowers, Christopher ^e   Taylor, Michael ^c   Hainsworth, John ^f   Cerhan, James R ^g   Zelenetz, Andrew D ^b   Hirata, Jamie ^c   Miller, Thomas P ^h  

^a UNIVERSITY OF ROCHESTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e EMORY UNIVERSITY   (United States)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; RITUXIMAB;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DATA BASE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; LYMPHOMA, FOLLICULAR; MIDDLE AGED; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84866745624     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.6546     Document Type: Article

References (39)

1. Fisher SG, Fisher RI: The epidemiology of non-Hodgkin's lymphoma. Oncogene 23:6524-6534, 2004 (Pubitemid 39265515)
2. Surveillance, Epidemiology, and End Results (SEER) Program: SEER*Stat Database: Incidence - Released April 2011 on the basis of the November 2010 submission. Bethesda, MD, National Cancer Institute, Surveillance Research Program, Cancer Statistics Branch, 2011. http://www.seer.cancer.gov
3. Zelenetz AD, Abramson JS, Advani RH, et al: Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 9:484-560, 2011
4. Mauch P: Follicular non-Hodgkin's lymphoma: The role of radiation therapy. Ann Hematol 80:B63-B65, 2001 (suppl 3)
5. Pugh TJ, Ballonoff A, Newman F, et al: Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: A Surveillance, Epidemiology, and End Results database analysis. Cancer 116:3843-3851, 2010
6. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the National LymphoCare Study. J Clin Oncol 27:1202-1208, 2009
7. Wennekes L, Ottevanger PB, Raemaekers JM, et al: Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma. J Clin Oncol 29:1436-1444, 2011
8. Grol R, Grimshaw J: From best evidence to best practice: Effective implementation of change in patients' care. Lancet 362:1225-1230, 2003 (Pubitemid 37255352)
9. Lawrence TS, Urba WJ, Steinberg SM, et al: Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiat Oncol Biol Phys 14:417-424, 1988 (Pubitemid 19241694)
10. Pendlebury S, el Awadi M, Ashley S, et al: Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 36:167-171, 1995
11. Soubeyran P, Eghbali H, Bonichon F, et al: Localized follicular lymphomas: Prognosis and survival of stages I and II in a retrospective series of 103 patients. Radiother Oncol 13:91-98, 1988
12. Taylor RE, Allan SG, McIntyre MA, et al: Low grade stage I and II non-Hodgkin's lymphoma: Results of treatment and relapse pattern following therapy. Clin Radiol 39:287-290, 1988
13. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al: Clinical stage 1 non-Hodgkin's lymphoma: Long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69:1088-1093, 1994 (Pubitemid 24161865)
14. Wilder RB, Jones D, Tucker SL, et al: Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51:1219-1227, 2001 (Pubitemid 33116314)
15. Guadagnolo BA, Li S, Neuberg D, et al: Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 64:928-934, 2006 (Pubitemid 43183595)
16. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996 (Pubitemid 26105537)
17. Hoskin P, Lowry L, Smith P, et al: Radiation dose for local control in non-Hodgkin lymphoma: British National Lymphoma Investigation randomized trial. Ann Oncol 22:iv90, 2011
18. Engelhard M, Unterhalt M, Hansmann M, et al: Follicular lymphoma: Curability by radiotherapy in limited stage nodal disease? Updated results of a randomized trial. Ann Oncol 22:iv90, 2011
19. Haas RL, Poortmans P, de Jong D, et al: High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21:2474-2480, 2003 (Pubitemid 46606327)
20. Knoops L, Haas R, de Kemp S, et al: In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 110:1116-1122, 2007 (Pubitemid 47281406)
21. Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol 22:1454-1459, 2004 (Pubitemid 41103628)
22. Seymour JF, Pro B, Fuller LM, et al: Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21:2115-2122, 2003 (Pubitemid 46606360)
23. Kelsey SM, Newland AC, Hudson GV, et al: A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol 11:19-25, 1994 (Pubitemid 24266261)
24. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
25. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
26. Friedberg JW, Chengazi V: PET scans in the staging of lymphoma: Current status. Oncologist 8:438-447, 2003 (Pubitemid 37238871)
27. Chau I, Jones R, Cunningham D, et al: Outcome of follicular lymphoma grade 3: Is anthracycline necessary as front-line therapy? Br J Cancer 89:36-42, 2003 (Pubitemid 36897932)
28. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993 (Pubitemid 23105672)
29. Miller TP, LeBlanc M, Grogan TM, et al: Follicular lymphomas: Do histologic subtypes predict outcome? Hematol Oncol Clin North Am 11:893-900, 1997 (Pubitemid 27431151)
30. Shustik J, Quinn M, Connors JM, et al: Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol 22:1164-1169, 2011
31. LaCasce AS, Kho ME, Friedberg JW, et al: Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol 26:5107-5112, 2008
32. Clarke CA, Glaser SL, Dorfman RF, et al: Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: Reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev 13:138-143, 2004 (Pubitemid 38116631)
33. Dick F, VanLier S, Banks P, et al: Use of the working formulation for non-Hodgkin's lymphoma in epidemiologic studies: Agreement between reported diagnoses and a panel of experienced pathologists. J Natl Cancer Inst 78:1137-1144, 1987 (Pubitemid 17113645)
34. Federico M, Guglielmi C, Luminari S, et al: Prognostic relevance of serum β2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. Haematologica 92:1482-1488, 2007 (Pubitemid 350144123)
35. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005 (Pubitemid 46224008)
36. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
37. Martinelli G, Schmitz SF, Utiger U, et al: Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 28:4480-4484, 2010
38. Staudt LM: A closer look at follicular lymphoma. N Engl J Med 356:741-742, 2007
39. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004 (Pubitemid 39507628)